Related Experiment Video
Updated: Jun 5, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Effects of Botulinum Toxin Type A Treatment on Clinical and Biophysical Parameters in Patients With
Buğra Burç Dağtaş1, Ozan Erdem2, Tuğba İlter Güneç1
1Department of Dermatology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey.
Background:
Erythematotelangiectatic rosacea (ETR) lacks a gold-standard treatment. Recent studies show that intradermal Botulinum Toxin-A (BoNT-A) is effective for erythema, though objective data are limited.
Objective:
This study aims to evaluate the efficacy and tolerability of intradermal BoNT-A in patients with ETR.
Methods:
In this randomized, double-blind, split-face study, 30 patients were enrolled. One side of the face received 15 units of BoNT-A, reconstituted in 10 mL of saline, while the control side received saline injections. Assessments were made at baseline and 1-month posttreatment. Clinician's Erythema Assessment (CEA) scale and Patient Self-Assessment (PSA) scores were recorded. Erythema and Melanin Index measurements using a Mexameter. Background erythema was assessed through dermatoscopy, while vascular structure and density were evaluated using Investigative Global Assessment (IGA) scores through videocapillaroscopy.
Results:
The BoNT-A-treated side demonstrated significant reductions in CEA scores, Erythema Index, and dermatoscopic background erythema, while no significant changes were observed on the saline control side. IGA scores indicated a significant response to treatment on the BoNT-A side. Patient Self-Assessment scores improved on both sides. No serious adverse events requiring hospitalization were reported.
Conclusion:
Intradermal BoNT-A effectively reduces erythema and vascular density in patients with ETR and is well-tolerated.
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Local Anesthetics: Pharmacokinetics

